Antibody- and Radionuclide Drug Conjugates: Advanced vial solutions for cutting-edge cancer treatments

The latest innovations in drug technologies seek to bring cancer treatment to the next level. For example, monoclonal antibodies' targeting ability can be combined with a cytotoxic (Antibody Drug Conjugates) or radioactive molecule (Radionucleotide Drug Conjugates). Due to their precision, these drugs offer a promising alternative to common radiation or chemotherapy, potentially increasing effectiveness and reducing side effects for patients.

However, these drugs have complex structures that pose certain challenges in processing and storage in primary packaging. Stability issues often necessitate lyophilization, while liquid formulations can be affected by glass leachables. Additionally, light sensitivity may present further hurdles. Watch this Pharmaversity® session and learn what vial solutions SCHOTT Pharma offers to address these challenges.